Hua-Jun Gao1, Ya-Jing Chen1, Duo Zuo1, Ming-Ming Xiao1, Ying Li1, Hua Guo1, Ning Zhang1, Rui-Bing Chen1. 1. 1 Research Center of Basic Medical Sciences & School of Medical Laboratory, Tianjin Medical University, Tianjin 300070, China ; 2 Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
Abstract
OBJECTIVE: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Novel serum biomarkers are required to increase the sensitivity and specificity of serum screening for early HCC diagnosis. This study employed a quantitative proteomic strategy to analyze the differential expression of serum glycoproteins between HCC and normal control serum samples. METHODS: Lectin affinity chromatography (LAC) was used to enrich glycoproteins from the serum samples. Quantitative mass spectrometric analysis combined with stable isotope dimethyl labeling and 2D liquid chromatography (LC) separations were performed to examine the differential levels of the detected proteins between HCC and control serum samples. Western blot was used to analyze the differential expression levels of the three serum proteins. RESULTS: A total of 2,280 protein groups were identified in the serum samples from HCC patients by using the 2D LC-MS/MS method. Up to 36 proteins were up-regulated in the HCC serum, whereas 19 proteins were down-regulated. Three differential glycoproteins, namely, fibrinogen gamma chain (FGG), FOS-like antigen 2 (FOSL2), and α-1,6-mannosylglycoprotein 6-β-N-acetylglucosaminyltransferase B (MGAT5B) were validated by Western blot. All these three proteins were up-regulated in the HCC serum samples. CONCLUSION: A quantitative glycoproteomic method was established and proven useful to determine potential novel biomarkers for HCC.
OBJECTIVE:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Novel serum biomarkers are required to increase the sensitivity and specificity of serum screening for early HCC diagnosis. This study employed a quantitative proteomic strategy to analyze the differential expression of serum glycoproteins between HCC and normal control serum samples. METHODS: Lectin affinity chromatography (LAC) was used to enrich glycoproteins from the serum samples. Quantitative mass spectrometric analysis combined with stable isotope dimethyl labeling and 2D liquid chromatography (LC) separations were performed to examine the differential levels of the detected proteins between HCC and control serum samples. Western blot was used to analyze the differential expression levels of the three serum proteins. RESULTS: A total of 2,280 protein groups were identified in the serum samples from HCC patients by using the 2D LC-MS/MS method. Up to 36 proteins were up-regulated in the HCC serum, whereas 19 proteins were down-regulated. Three differential glycoproteins, namely, fibrinogen gamma chain (FGG), FOS-like antigen 2 (FOSL2), and α-1,6-mannosylglycoprotein 6-β-N-acetylglucosaminyltransferase B (MGAT5B) were validated by Western blot. All these three proteins were up-regulated in the HCC serum samples. CONCLUSION: A quantitative glycoproteomic method was established and proven useful to determine potential novel biomarkers for HCC.
Entities:
Keywords:
Glycoprotein; hepatocellular carcinoma (HCC); mass spectrometry; proteomics; serum
Authors: Stephan Mathas; Stephan Kreher; Karen J Meaburn; Korinna Jöhrens; Björn Lamprecht; Chalid Assaf; Wolfram Sterry; Marshall E Kadin; Masanori Daibata; Stefan Joos; Michael Hummel; Harald Stein; Martin Janz; Ioannis Anagnostopoulos; Evelin Schrock; Tom Misteli; Bernd Dörken Journal: Proc Natl Acad Sci U S A Date: 2009-03-25 Impact factor: 11.205
Authors: H Oka; A Saito; K Ito; T Kumada; S Satomura; H Kasugai; Y Osaki; T Seki; M Kudo; M Tanaka Journal: J Gastroenterol Hepatol Date: 2001-12 Impact factor: 4.029
Authors: T Nakayama; K Hieshima; T Arao; Z Jin; D Nagakubo; A-K Shirakawa; Y Yamada; M Fujii; N Oiso; A Kawada; K Nishio; O Yoshie Journal: Oncogene Date: 2007-12-10 Impact factor: 9.867
Authors: Shin-Ichiro Maruya; Hyung-Woo Kim; Randal S Weber; Jack J Lee; Merril Kies; Mario A Luna; John G Batsakis; Adel K El-Naggar Journal: J Mol Diagn Date: 2004-08 Impact factor: 5.568
Authors: Charis-Patricia Segeritz; Sheikh Tamir Rashid; Miguel Cardoso de Brito; Maria Paola Serra; Adriana Ordonez; Carola Maria Morell; Joseph E Kaserman; Pedro Madrigal; Nicholas R F Hannan; Laurent Gatto; Lu Tan; Andrew A Wilson; Kathryn Lilley; Stefan J Marciniak; Bibek Gooptu; David A Lomas; Ludovic Vallier Journal: J Hepatol Date: 2018-06-05 Impact factor: 25.083